CLINICAL RESEARCH: GENETICS AND CORONARY ARTERY DISEASE
Association of the Trp719Arg Polymorphism in Kinesin-Like Protein 6 With Myocardial Infarction and Coronary Heart Disease in 2 Prospective TrialsThe CARE and WOSCOPS Trials
Olga A. Iakoubova, MD, PhD*,*,
Carmen H. Tong, BS*,
Charles M. Rowland, MS*,
Todd G. Kirchgessner, PhD ,
Bradford A. Young, PhD*,
Andre R. Arellano, BS*,
Dov Shiffman, PhD*,
Marc S. Sabatine, MD, MPH ,
Hannia Campos, PhD ,
Christopher J. Packard, DSc||,
Marc A. Pfeffer, MD, PhD,
Thomas J. White, PhD*,
Eugene Braunwald, MD, FACC,
James Shepherd, PhD||,
James J. Devlin, PhD* and
Frank M. Sacks, MD,
* Celera, Inc., Alameda, California
Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey
Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
Harvard School of Public Health, Boston, Massachusetts
|| University of Glasgow and Royal Infirmary, Glasgow, United Kingdom.
Manuscript received May 8, 2007;
accepted May 23, 2007.
* Reprint requests and correspondence: Dr. Olga A. Iakoubova, Celera, Inc., 1401 Harbor Bay Parkway, Alameda, California 94502. (Email: olga.iakoubova{at}celera.com).
Objectives: We asked whether 35 genetic polymorphisms, previously found to be associated with cardiovascular disease, were associated with myocardial infarction (MI) in the CARE (Cholesterol and Recurrent Events) trial and with coronary heart disease (CHD) in the WOSCOPS (West of Scotland Coronary Prevention Study) trial and whether the risk associated with these polymorphisms could be reduced by pravastatin treatment.
Background: Identification of genetic polymorphisms associated with CHD may improve assessment of CHD risk and understanding of disease pathophysiology.
Methods: We tested the association between genotype and recurrent MI in the CARE study and between genotype and primary CHD in the WOSCOPS trial using regression models that adjusted for conventional risk factors: Cox proportional hazards models for the CARE study and conditional logistic regression models for a nested case-control study of the WOSCOPS trial.
Results: We found that Trp719Arg (rs20455) in KIF6 was associated with coronary events. KIF6 encodes kinesin-like protein 6, a member of the molecular motor superfamily. In placebo-treated patients, carriers of the KIF6 719Arg allele (59.4% of the CARE trial cohort) had a hazard ratio of 1.50 (95% confidence interval [CI] 1.05 to 2.15) in the CARE trial and an odds ratio of 1.55 (95% CI 1.14 to 2.09) in the WOSCOPS trial. Among carriers, the absolute risk reduction by pravastatin was 4.89% (95% CI 1.81% to 7.97%) in the CARE trial and 5.49% (95% CI 3.52% to 7.46%) in the WOSCOPS trial.
Conclusions: In both the CARE and the WOSCOPS trials, carriers of the KIF6 719Arg allele had an increased risk of coronary events, and pravastatin treatment substantially reduced that risk.
|
Abbreviations and Acronyms
| | CHD = coronary heart disease | | CI = confidence interval | | DNA = deoxyribonucleic acid | | HDL-C = high-density lipoprotein cholesterol | | HR = hazard ratio | | LDL-C = low-density lipoprotein cholesterol | | MI = myocardial infarction | | OR = odds ratio | | SNP = single nucleotide polymorphism |
|
Related Article
-
Surprises of the Genome and "Personalized" Medicine
- Ali J. Marian
J. Am. Coll. Cardiol. 2008 51: 456-458.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
J. L. Mega, D. A. Morrow, A. Brown, C. P. Cannon, and M. S. Sabatine
Identification of Genetic Variants Associated With Response to Statin Therapy
Arterioscler Thromb Vasc Biol,
September 1, 2009;
29(9):
1310 - 1315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F.R. Stewart, S. Dandona, L. Chen, O. Assogba, M. Belanger, G. Ewart, R. LaRose, H. Doelle, K. Williams, G. A. Wells, et al.
Kinesin Family Member 6 Variant Trp719Arg Does Not Associate With Angiographically Defined Coronary Artery Disease in the Ottawa Heart Genomics Study
J. Am. Coll. Cardiol.,
April 21, 2009;
53(16):
1471 - 1472.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Plump and P. Y. Lum
Genomics and cardiovascular drug development.
J. Am. Coll. Cardiol.,
March 31, 2009;
53(13):
1089 - 1100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V.G. Bruschke and J. W. Jukema
Aggressive Therapy Is Not Always the Best Therapy
J. Am. Coll. Cardiol.,
September 9, 2008;
52(11):
921 - 923.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Iakoubova, J. Shepherd, and F. Sacks
Association of the 719Arg variant of KIF6 with both increased risk of coronary events and with greater response to statin therapy.
J. Am. Coll. Cardiol.,
June 3, 2008;
51(22):
2195 - 2195.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Marian
Reply.
J. Am. Coll. Cardiol.,
June 3, 2008;
51(22):
2195 - 2196.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Braunwald
The Management of Heart Failure: The Past, the Present, and the Future
Circ Heart Fail,
May 1, 2008;
1(1):
58 - 62.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Shiffman, D. I. Chasman, R. Y.L. Zee, O. A. Iakoubova, J. Z. Louie, J. J. Devlin, and P. M. Ridker
A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
444 - 448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. A. Iakoubova, M. S. Sabatine, C. M. Rowland, C. H. Tong, J. J. Catanese, K. Ranade, K. L. Simonsen, T. G. Kirchgessner, C. P. Cannon, J. J. Devlin, et al.
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
449 - 455.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Marian
Surprises of the genome and "personalized" medicine.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
456 - 458.
[Full Text]
[PDF]
|
|
|
|
